000140801 001__ 140801
000140801 005__ 20240321220857.0
000140801 0247_ $$2doi$$a10.1001/jamaneurol.2019.0423
000140801 0247_ $$2pmid$$apmid:30933216
000140801 0247_ $$2pmc$$apmc:PMC6563569
000140801 0247_ $$2ISSN$$a0003-9942
000140801 0247_ $$2ISSN$$a0375-8540
000140801 0247_ $$2ISSN$$a1538-3687
000140801 0247_ $$2ISSN$$a2168-6149
000140801 0247_ $$2ISSN$$a2168-6157
000140801 0247_ $$2ISSN$$a2330-9644
000140801 0247_ $$2altmetric$$aaltmetric:58271169
000140801 037__ $$aDZNE-2020-07123
000140801 041__ $$aEnglish
000140801 082__ $$a610
000140801 1001_ $$0P:(DE-HGF)0$$aGardiner, Sarah L$$b0$$eCorresponding author
000140801 245__ $$aPrevalence of Carriers of Intermediate and Pathological Polyglutamine Disease-Associated Alleles Among Large Population-Based Cohorts.
000140801 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2019
000140801 264_1 $$2Crossref$$3print$$bAmerican Medical Association (AMA)$$c2019-06-01
000140801 3367_ $$2DRIVER$$aarticle
000140801 3367_ $$2DataCite$$aOutput Types/Journal article
000140801 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1593428689_12126
000140801 3367_ $$2BibTeX$$aARTICLE
000140801 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140801 3367_ $$00$$2EndNote$$aJournal Article
000140801 520__ $$aNine hereditary neurodegenerative diseases are known as polyglutamine diseases, including Huntington disease, 6 spinocerebellar ataxias (SCAs) (SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17), dentatorubral-pallidoluysion atrophy, and spinal bulbar muscular atrophy.To determine the prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles among the general population.This observational cross-sectional study included data from 5 large European population-based cohorts that were compiled between 1997 and 2012, and the analyses were conducted in 2018. In total, 16 547 DNA samples were obtained from participants of the 5 cohorts. Individuals with a lifetime diagnosis of major depression were excluded (n = 2351). In the remaining 14 196 participants without an established polyglutamine disease diagnosis, the CAG repeat size in both alleles of all 9 polyglutamine disease-associated genes (PDAGs) (ie, ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, TBP, HTT, ATN1, and AR) was determined.The number of CAG repeats in the alleles of the 9 PDAGs.The number of individuals with alleles within the intermediate or pathological range per PDAG, as well as differences in sex, age, and body mass index between individuals carrying alleles within the normal or intermediate range and individuals carrying alleles within the pathological range of PDAGs.In the 14 196 analyzed participants (age range, 18-99 years; 56.3% female), 10.7% had a CAG repeat number within the intermediate range of at least 1 PDAG. Moreover, up to 1.3% of the participants had a CAG repeat number within the disease-causing range, predominantly in the lower pathological range associated with elderly onset. No differences in sex, age, or body mass index were found between individuals with CAG repeat numbers within the pathological range and individuals with CAG repeat numbers within the normal or intermediate range.These results indicate a high prevalence of individuals carrying intermediate and pathological ranges of polyglutamine disease-associated alleles among the general population. Therefore, a substantially larger proportion of individuals than previously estimated may be at risk of developing a polyglutamine disease later in life or bearing children with a de novo mutation.
000140801 536__ $$0G:(DE-HGF)POF3-345$$a345 - Population Studies and Genetics (POF3-345)$$cPOF3-345$$fPOF III$$x0
000140801 588__ $$aDataset connected to CrossRef, PubMed,
000140801 7001_ $$aBoogaard, Merel W$$b1
000140801 7001_ $$aTrompet, Stella$$b2
000140801 7001_ $$ade Mutsert, Renée$$b3
000140801 7001_ $$aRosendaal, Frits R$$b4
000140801 7001_ $$aGussekloo, Jacobijn$$b5
000140801 7001_ $$aJukema, J Wouter$$b6
000140801 7001_ $$aRoos, Raymund A C$$b7
000140801 7001_ $$0P:(DE-2719)2812578$$aAziz, Ahmad$$b8$$eLast author$$udzne
000140801 77318 $$2Crossref$$3journal-article$$a10.1001/jamaneurol.2019.0423$$b : American Medical Association (AMA), 2019-06-01$$n6$$p650$$tJAMA Neurology$$v76$$x2168-6149$$y2019
000140801 773__ $$0PERI:(DE-600)2701924-X$$a10.1001/jamaneurol.2019.0423$$gVol. 76, no. 6, p. 650 -$$n6$$p650$$q76:6<650 -$$tJAMA neurology$$v76$$x2168-6149$$y2019
000140801 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563569
000140801 909CO $$ooai:pub.dzne.de:140801$$pVDB
000140801 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812578$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000140801 9131_ $$0G:(DE-HGF)POF3-345$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vPopulation Studies and Genetics$$x0
000140801 9141_ $$y2019
000140801 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA NEUROL : 2021$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-05
000140801 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bJAMA NEUROL : 2021$$d2022-11-05
000140801 9201_ $$0I:(DE-2719)1012001$$kAG Breteler 1$$lPopulation Health Sciences$$x0
000140801 980__ $$ajournal
000140801 980__ $$aVDB
000140801 980__ $$aI:(DE-2719)1012001
000140801 980__ $$aUNRESTRICTED